Olympus and Revival Launch Swan EndoSurgical to Advance GI Robotics

Olympus has announced a major strategic partnership with Texas-based Revival Healthcare Capital to co-found Swan EndoSurgical, a new company focused on developing a robotic system for endoluminal gastrointestinal (GI) interventions. Backed by an initial investment of at least $65 million—and potentially up to $458 million based on milestone achievements—this collaboration represents a significant move to accelerate innovation in minimally invasive therapeutic technologies.

Swan EndoSurgical’s platform aims to enhance precision and efficiency in GI procedures by enabling safe, early, and organ-sparing treatment of lesions and tumors. Leveraging robotic capabilities such as flexible arm deployment and enhanced maneuverability within the GI tract, the system is designed to overcome the limitations of current manual endoscopy tools and extend the reach of advanced therapeutic procedures to a wider patient population.

“This partnership marks a pivotal step in Olympus’ strategy to expand into endoluminal robotics,” said Bob White, President and CEO of Olympus. “Through Swan, we’re building a future where more physicians can perform advanced procedures with improved ergonomics, leading to better outcomes and faster recoveries.”

Revival will hold a majority equity stake in Swan, with Olympus retaining a significant position and an option to acquire the company at a predetermined value. The structure allows Swan to operate with startup-level agility while benefiting from Olympus’ global expertise in GI endoscopy and imaging technologies.

Rick Anderson, Chairman of Revival, emphasized the value of external innovation models: “This partnership showcases how our build-to-buy approach can accelerate impactful solutions for both companies. Together, we’re setting a new standard for collaborative medical device development.”

Headquartered in the U.S., Swan EndoSurgical is led by a seasoned executive team tasked with driving technical, clinical, and commercial development of the robotic platform. The technology could eventually expand beyond GI applications, further broadening its clinical value and potential impact on minimally invasive care.